PDS Biotechnology Corp
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies. The company's lead product candidate is Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are in preclinical trials, includin… Read more
PDS Biotechnology Corp (PDSB) - Total Liabilities
Latest total liabilities as of September 2025: $25.25 Million USD
Based on the latest financial reports, PDS Biotechnology Corp (PDSB) has total liabilities worth $25.25 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
PDS Biotechnology Corp - Total Liabilities Trend (2012–2024)
This chart illustrates how PDS Biotechnology Corp's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
PDS Biotechnology Corp Competitors by Total Liabilities
The table below lists competitors of PDS Biotechnology Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
REC Silicon ASA
PINK:RNWEF
|
USA | $582.30 Million |
|
Savezone I C
KO:067830
|
Korea | ₩90.66 Billion |
|
Kartonsan Karton Sanayi ve Ticaret AS
IS:KARTN
|
Turkey | TL1.69 Billion |
|
Maiden Holdings Ltd
NASDAQ:MHLD
|
USA | $1.20 Billion |
|
Huang Long Development Co Ltd
TWO:3512
|
Taiwan | NT$2.58 Billion |
|
Wellpool Co Ltd
TWO:8424
|
Taiwan | NT$181.62 Million |
|
Lu Hai Holding Corp
TW:2115
|
Taiwan | NT$1.42 Billion |
|
Shufersal
TA:SAE
|
Israel | ILA11.48 Billion |
Liability Composition Analysis (2012–2024)
This chart breaks down PDS Biotechnology Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.09 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.67 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.73 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how PDS Biotechnology Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for PDS Biotechnology Corp (2012–2024)
The table below shows the annual total liabilities of PDS Biotechnology Corp from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $26.35 Million | -20.76% |
| 2023-12-31 | $33.26 Million | +0.77% |
| 2022-12-31 | $33.01 Million | +727.74% |
| 2021-12-31 | $3.99 Million | +6.03% |
| 2020-12-31 | $3.76 Million | +34.62% |
| 2019-12-31 | $2.79 Million | -56.23% |
| 2018-12-31 | $6.38 Million | -78.90% |
| 2017-12-31 | $30.25 Million | +39.80% |
| 2016-12-31 | $21.64 Million | +86.29% |
| 2015-12-31 | $11.62 Million | -74.12% |
| 2014-12-31 | $44.88 Million | +86.35% |
| 2013-12-31 | $24.08 Million | +578.78% |
| 2012-12-31 | $3.55 Million | -- |